Meningococcal carriage 7 years after introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from four cross-sectional carriage surveys - 26/11/20
, Emmanuel Sampo, MSc b, Kambiré Dinanibè, PhD c, Issaka Yaméogo, MD d, Malika Congo-Ouédraogo, PharmD e, Mamadou Tamboura, MSc c, Guetawendé Sawadogo, MPH d, Kalifa Ouattara, BS e, Mahamadou Sanou, PhD c, Tanga Kiemtoré, MSc d, Gerard Dioma, PharmD e, Barnabé Sanon, MD f, Hermann Somlaré, MSc e, Augustin Kyetega, BS c, Absatou Ky Ba, MD g, Flavien Aké, MSc h, Félix Tarbangdo, MSc h, Frederic Acho Aboua, BS h, Yvette Donnou, BS h, Idrissa Kamaté i, Jaymin C Patel, PhD a, Susanna Schmink, BS a, Michael W Spiller, PhD a, Nadav Topaz, MSc a, Ryan Novak, PhD a, Xin Wang, PhD a, Brice Bicaba, MD d, Lassana Sangaré, ProfPhD e, Rasmata Ouédraogo-Traoré, ProfPhD c, Paul A Kristiansen, PhD jSummary |
Background |
In the first 2 years after a nationwide mass vaccination campaign of 1–29-year-olds with a meningococcal serogroup A conjugate vaccine (MenAfriVac) in Burkina Faso, carriage and disease due to serogroup A Neisseria meningitidis were nearly eliminated. We aimed to assess the long-term effect of MenAfriVac vaccination on meningococcal carriage and herd immunity.
Methods |
We did four cross-sectional studies of meningococcal carriage in people aged 9 months to 36 years in two districts of Burkina Faso between May 2, 2016, and Nov 6, 2017. Demographic information and oropharyngeal swabs were collected. Meningococcal isolates were characterised using whole-genome sequencing.
Findings |
Of 14 295 eligible people, 13 758 consented and had specimens collected and laboratory results available, 1035 of whom were meningococcal carriers. Accounting for the complex survey design, prevalence of meningococcal carriage was 7·60% (95% CI 5·67–9·52), including 6·98% (4·86–9·11) non-groupable, 0·48% (0·01–0·95) serogroup W, 0·10% (0·01–0·18) serogroup C, 0·03% (0·00–0·80) serogroup E, and 0% serogroup A. Prevalence ranged from 5·44% (95% CI 4·18–6·69) to 9·14% (6·01–12·27) by district, from 4·67% (2·71–6·64) to 11·17% (6·75–15·59) by round, and from 3·39% (0·00–8·30) to 10·43% (8·08–12·79) by age group. By clonal complex, 822 (88%) of 934 non-groupable isolates were CC192, all 83 (100%) serogroup W isolates were CC11, and nine (69%) of 13 serogroup C isolates were CC10217.
Interpretation |
Our results show the continued effect of MenAfriVac on serogroup A meningococcal carriage, for at least 7 years, among vaccinated and unvaccinated cohorts. Carriage prevalence of epidemic-prone serogroup C CC10217 and serogroup W CC11 was low. Continued monitoring of N meningitidis carriage will be crucial to further assess the effect of MenAfriVac and inform the vaccination strategy for future multivalent meningococcal vaccines.
Funding |
Bill & Melinda Gates Foundation and Gavi, the Vaccine Alliance.
Le texte complet de cet article est disponible en PDF.Plan
Vol 20 - N° 12
P. 1418-1425 - décembre 2020 Retour au numéro
Article précédent
- Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study
- Richard Kuehl, Laura Morata, Christian Boeing, Isaac Subirana, Harald Seifert, Siegbert Rieg, Winfried V Kern, Hong Bin Kim, Eu Suk Kim, Chun-Hsing Liao, Robert Tilley, Luis Eduardo Lopez-Cortés, Martin J Llewelyn, Vance G Fowler, Guy Thwaites, José Miguel Cisneros, Matt Scarborough, Emmanuel Nsutebu, Mercedes Gurgui Ferrer, José L Pérez, Gavin Barlow, Susan Hopkins, Hugo Guillermo Ternavasio-de la Vega, M Estée Török, Peter Wilson, Achim J Kaasch, Alex Soriano, International Staphylococcus aureus collaboration study group and the ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis, Richard Kuehl, Laura Morata, Christian Boeing, Isaac Subirana, Harald Seifert, Siegbert Rieg, Winfried V. Kern, Hong Bin Kim, Eu Suk Kim, Chun-Hsing Liao, Robert Tilley, Luis Eduardo Lopez-Cortés, Martin J. Llewelyn, Vance G. Fowler, Guy Thwaites, José Miguel Cisneros, Matt Scarborough, Emmanuel Nsutebu, Mercedes Gurgui Ferrer, José L. Pérez, Gavin Barlow, Susan Hopkins, Hugo Guillermo Ternavasio-de la Vega, Estée Török, Peter Wilson, Achim J. Kaasch, Alex Soriano, Christian Bernasch, Norma Jung, Karuna Lamarca Soria, Maria Alba Rivera Martínez, Nuria Prim, José Antonio Martínez, Miguel Marcos, Jesús Rodríguez Baño, Marina De Cueto, Kyoung-Ho Sung, Chung-Jong Kim, Chang Kyung Kang, Jung In Park, Stephen Morris-Jones, Musa Kamfose, Bernadette Young, Hannah Gott, Theodore Gouliouris, Luke Bedford, James Price
- Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial
- Shabir A Madhi, Eleonora AML Mutsaerts, Alane Izu, Welekazi Boyce, Sutika Bhikha, Benit T Ikulinda, Lisa Jose, Anthonet Koen, Amit J Nana, Andrew Moultrie, Lucy Roalfe, Adam Hunt, David Goldblatt, Clare L Cutland, Jeffrey R Dorfman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?